Cyberlux Corporation Reports Q1 2025 Results: Strategic Advancements in UAS, Communications, and Global Services
' During SOF Week 2025, Cyberlux UAS completed the development of two new Group 1 rotary-wing unmanned aircraft systems, including a heavy-lift platform engineered for the U.S. Special Operations community,' said Mark Schmidt, CEO of Cyberlux Corporation. 'These advanced drones deliver increased endurance, heavier payload capacity, and optimized performance in dense electronic warfare (EW) environments—precisely the edge capabilities our warfighters require.'
Product & Partnership Milestones in Q1 2025
Strategic Partnership with TrellisWare Technologies, Inc. – Cyberlux UAS and TrellisWare formed a key integration agreement to embed TrellisWare's low-latency, anti-jam waveform into Cyberlux's newest UAS platforms. This advancement enables First Person View (FPV) operations in contested electromagnetic environments, a critical capability for modern battlefield scenarios.
Advanced Autonomy with OKSI – Cyberlux initiated a strategic partnership with Optical Knowledge Systems, Inc. (OKSI) to integrate its OMNISCIENCE™ autonomy suite, enabling autonomous navigation and target acquisition in GPS- and RF-denied environments.
Datron Military Communications Expansion – The Datron team launched a new family of MESH/MANET radio systems for high-speed data delivery at the tactical edge. These systems, available in body-worn, base station, and OEM board formats, are built for integration into UAS, ISR sensors, autonomous ground vehicles, and other advanced platforms.
GIS Program Growth – The Global Integration Services (GIS) team expanded its Foreign Military Sales (FMS) border security programs to include three additional U.S. allies, bringing the total to seven partner nations in the Middle East and Africa. Funding decisions for these programs are expected in Q4 2025.
'Our Q1 performance underscores Cyberlux's rapid advancement across unmanned systems, tactical communications, and global integration,' said Schmidt. 'With a $45 million backlog and strategic programs ramping, we're entering the second quarter positioned for accelerated growth and major execution milestones.'
Q1 2025 Financial Highlights
Total revenue of $5.1 million, reflecting active contract delivery and operational execution.
Operating loss narrowed by $2.5 million, from a $4.2 million loss in Q1 2024 to a $1.7 million loss in Q1 2025, driven by improved margins and cost optimization.
$5.7 million in cash and accounts receivable on the balance sheet at quarter-end.
Finalized a key drone contract modification, positioning the company for significant revenue acceleration in Q2 and beyond.
Total contract backlog reached $45 million, reflecting robust demand
Review the latest release here:
About Cyberlux Corporation
Cyberlux Corporation (OTC: CYBL) is an advanced technology platform delivering disruptive innovation in unmanned aerial systems (UAS), secure communications, and Global Integration Services (GIS). Headquartered in Research Triangle Park, NC, Cyberlux powers mission-critical capabilities for U.S. and allied defense and government partners worldwide.
For more information, visit www.cyberlux.com.
SAFE HARBOR STATEMENT
This Press Release may contain forward-looking statements that can be identified by terminology such as 'believes,' 'expects,' 'potential,' 'plans,' 'suggests,' 'may,' 'should,' 'could,' 'intends,' or similar expressions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's OTC/SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)
In a report released on August 7, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed yesterday at $58.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pauillac covers the Healthcare sector, focusing on stocks such as Sanofi, Formycon AG, and COSMO Pharmaceuticals N.V.. According to TipRanks, Pauillac has an average return of 11.7% and a 48.15% success rate on recommended stocks. In addition to Kepler Capital , Sandoz Group Ltd also received a Buy from Barclays's Emily Field in a report issued yesterday. However, on the same day, Jefferies downgraded Sandoz Group Ltd (Other OTC: SDZXF) to a Hold. SDZXF market cap is currently $24.67B and has a P/E ratio of 107.75.
Yahoo
5 hours ago
- Yahoo
Why Investors Were so High on Curaleaf Stock Thursday
Key Points As is common in the pot industry, Curaleaf posted a net loss in its second quarter. There were several reasons to be optimistic about its future, however. 10 stocks we like better than Curaleaf › Earnings season is always something of a nerve-shredding time for marijuana stock investors, as pot companies more often than not tend to post bottom-line losses. Sure enough, sector mainstay Curaleaf (OTC: CURLF) delivered a deficit in the second quarter, as its earnings release published after market close Wednesday revealed. However, it wasn't significantly deeper on a comparable basis. Meanwhile, there were other glimmers of hope in the document. As a result, bullish investors traded up Curaleaf stock on the day, powering it to a nearly 7% gain. Investor tolerance for loss For the quarter, Curaleaf posted total net revenue of more than $314 million, representing a slide from the over $342 million it earned in the same period of 2024. That net loss, meanwhile, was considerable but not much worse than in the year-ago frame; it deepened to $53 million ($0.07 per share) from nearly $49 million. Curaleaf continued to expand during the quarter, as it flicked the lights on in two dispensaries, one located in populous Florida (specifically the municipality of Winter Park, near Orlando) and the other in Lima, Ohio. On the product side, it launched a pair of new products, Anthem pre-rolled cannabis cigarettes and Select ACE oil. Perhaps more impactfully for the future, it was awarded a license to participate in the specialized marijuana market of another populous location, the country of Turkey. Its license gives it entry to that nation's medical pot market, which began at the end of July with a new law allowing for sales in pharmacies to qualifying patients. Looking for legalization As ever with marijuana stocks, they're probably not going to move significantly -- and sustainably -- until full-blown legalization (or at least decriminalization) is enacted in a major jurisdiction. All eyes are on the U.S., where halting efforts in this sphere have resulted in a patchwork of states where medical and/or recreational weed sale and consumption are permitted. Should you invest $1,000 in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,099,758!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Investors Were so High on Curaleaf Stock Thursday was originally published by The Motley Fool Sign in to access your portfolio
Business Upturn
10 hours ago
- Business Upturn
Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions
MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) — MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial and operational results for the first fiscal quarter ended June 30, 2025. Giorgio R. Saumat, ETST's CEO, commented: 'The first quarter of fiscal 2025 was a pivotal period for Earth Science Tech. We strategically deployed capital to acquire high-potential operating businesses that are now poised to enhance our diversified product and service offerings. This was a foundational quarter, setting the stage for the future. Our focus has now firmly shifted from acquisitions to maximizing the value and profitability of our current divisions, ensuring we capitalize on these strategic investments for our shareholders throughout the remainder of the fiscal year.' First Quarter Fiscal 2025 Financial Highlights Total Assets: Increased by 61% to $7.69 million as of June 30, 2025, up from $4.77 million in the prior-year period. Increased by 61% to $7.69 million as of June 30, 2025, up from $4.77 million in the prior-year period. Revenue: Generated $8.7 million as of June 30, 2025, an increase from $8.5 million in the prior-year period. Generated $8.7 million as of June 30, 2025, an increase from $8.5 million in the prior-year period. Shareholder Value: Reduced total common shares outstanding by 4.78% to 294,297,607 as of June 30, 2025, down from 309,067,711 shares in the prior-year period. Reduced total common shares outstanding by 4.78% to 294,297,607 as of June 30, 2025, down from 309,067,711 shares in the prior-year period. Cash Position: Reported cash and cash equivalents of $0.88 million. The decrease from $1.38 million in the prior-year period is a direct result of the strategic deployment of capital to fund key acquisitions. Strategic and Operational Update During the first quarter, ETST executed its growth strategy by investing in and acquiring a portfolio of operating businesses: Healthcare Expansion: Acquired 100% of Las Villas Health Care, Inc., a Coral Gables-based wellness center, and DOConsultation, LLC, a telehealth company. Acquired 100% of Las Villas Health Care, Inc., a Coral Gables-based wellness center, and DOConsultation, LLC, a telehealth company. Direct-to-Consumer Brands: Secured 80% ownership of Magnefuse, LLC, and Alicat, LLC (the 'MagneChef Portfolio'), DTC brands with a portfolio of unique patents and intellectual property. Secured 80% ownership of Magnefuse, LLC, and Alicat, LLC (the 'MagneChef Portfolio'), DTC brands with a portfolio of unique patents and intellectual property. Operational Infrastructure: Established a new customer service center in Doral, FL, to centralize support operations across all ETST divisions. Subsequent to the quarter's end, the Company has continued to execute on its operational goals: Enhanced Compliance: Joined the OTCID Tier on the OTC Markets, providing enhanced disclosure and transparency for investors. Joined the OTCID Tier on the OTC Markets, providing enhanced disclosure and transparency for investors. Compounding Pharmacy Expansion: The Company's MisterMeds, LLC division is now fully staffed and operational, actively dispensing in Texas and securing new accounts. The Company's MisterMeds, LLC division is now fully staffed and operational, actively dispensing in Texas and securing new accounts. Real Estate Development: Avenvi, LLC, an ETST division, has broken ground on its first residential development, with the project progressing on schedule. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684 [email protected]
